Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?

Basit Öğe Kaydı
dc.authorid0000-0001-9636-4113
dc.contributor.authorSolmaz, Şerife
dc.contributor.authorUzun, Özcan
dc.contributor.authorAcar, Celal
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorPişkin, Özden
dc.contributor.authorÖzsan, Hayri Güner
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorÜndar, Bülent
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorÖzcan, Mehmet Ali
dc.contributor.authorAlacacıoğlu, İnci
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:05Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:05Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000458270100001
dc.descriptionPubMed ID: 30498304
dc.description.abstractBACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. MATERIALS AND METHODS: We retrospectively examined the PLR, NLR, and MLR in a cohort of 186 newly diagnosed multiple myeloma (MM) patients. This study investigated the prognostic relevance of NLR, PLR, and MLR in MM patients. NLR, PLR, and MLR were calculated from whole blood counts before therapy. The Kaplan-Meier curves and multivariate Cox models were used for the evaluation of survival. RESULTS: Applying cutoff of 1.9 (NLR), 120.00 (PLR), and 0.27 (MLR), decreased PLR showed a negative impact on the outcome. Decreased PLR is an independent predictor for PFS and OS. There were no significant differences in median survival between the high and low NLR (P = 0.80) and MLR (P= 0.87) groups. CONCLUSIONS: In this study, thrombocytopenia and low PLR are associated with poor survival in MM patients does this P value apply to thrombocytopenia or low PLR and may serve as the cost-effective prognostic biomarker.
dc.identifier.citationSolmaz, Ş., Uzun, Ö., Acar, C., Sevindik, Ö. G., Pişkin, Ö., Özsan, H. G. ... Alacacıoğlu, İ. (2018). Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma? Journal of Laboratory Physicians, 10(4), 363-369. https://dx.doi.org/10.4103/JLP.JLP_36_18
dc.identifier.doi10.4103/JLP.JLP_36_18
dc.identifier.endpage369
dc.identifier.issn0974-2727
dc.identifier.issn0974-7826
dc.identifier.issue4
dc.identifier.startpage363
dc.identifier.urihttps://dx.doi.org/10.4103/JLP.JLP_36_18
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1878
dc.identifier.volume10
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofJournal of Laboratory Physiciansen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMultiple Myeloma
dc.subjectNeutrophil-to-lymphocyte Ratio
dc.subjectNew Prognostic Marker
dc.subjectPlatelet-to-lymphocyte Ratio
dc.titleIs the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sevindik, Omur Gokmen.pdf
Boyut:
884.05 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu